An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
Vignesh T. Packiam(Rutgers, The State University of New Jersey), Gary D. Steinberg(Rush University Medical Center), William R. Clark(Cancer Research UK), Karim Chamie(University of California, Los Angeles), Donald L. Lamm(The University of Texas System), Michael Kroeger(University of Nebraska Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Benjamin Fand, Alex Yeung(Genesys (United States)), Andrew Trainer(Adult and Pediatric Dermatology), Dominic Curran(Genesys (United States)), Ronald L. Davis(Wake Forest University), John Gutheil, Arthur Kuan(Genesys (United States)), A. Karim Kader(University of California San Diego), Igor Dumbadze
Cited by 250
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline
|The Journal of Urology|2012|487